BioCardia, Inc. Warrant
BCDAW
BCDAW was delisted on the 2nd of August, 2024.
0 hedge funds and large institutions have $0 invested in BioCardia, Inc. Warrant in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% less funds holding
Funds holding: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $1.58K → $0 (-$1.58K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$745 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$341 |
| 3 |
G
GenTrust
Miami,
Florida
|
-$196 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$130 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$95 |
BCDAW Hedge Fund Activity: Q3 2024 in Review
0 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioCardia, Inc. Warrant (BCDAW) for Q3 2024, worth a combined $0 — down 100% from $1.58K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BCDAW and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $745 sold.
- 0 institutional investors held BioCardia, Inc. Warrant (BCDAW) as of Q3 2024, down from 7 in Q2 2024.
- Funds reported $0 of BioCardia, Inc. Warrant stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new BioCardia, Inc. Warrant positions in Q3 2024 and 7 closed out, a net change of -7 holders.
- The largest BioCardia, Inc. Warrant seller in Q3 2024 was Citadel Advisors, an estimated $745 sold.
Based on aggregated 13F filings for Q3 2024.